- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07426757
진행성 암 환자에서 PF-07994525를 평가하기 위한 개방형 연구
진행성 악성 종양 환자를 대상으로 PF-07994525를 평가하기 위한 개방형 1상 연구
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- 모병
- Colorado Blood Cancer Institute
-
Denver, Colorado, 미국, 80218
- 모병
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- 모병
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven, Connecticut, 미국, 06510
- 모병
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven, Connecticut, 미국, 06510
- 모병
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven, Connecticut, 미국, 06511
- 모병
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven, Connecticut, 미국, 06473
- 모병
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables, Florida, 미국, 33146
- 모병
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs, Florida, 미국, 33065
- 모병
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach, Florida, 미국, 33442
- 모병
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral, Florida, 미국, 33166
- 모병
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood, Florida, 미국, 33021
- 모병
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami, Florida, 미국, 33136
- 모병
- Sylvester Comprehensive Cancer Center
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Hospital and Clinics
-
Miami, Florida, 미국, 33176
- 모병
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami, Florida, 미국, 33181
- 모병
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation, Florida, 미국, 33324
- 모병
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta, Georgia, 미국, 30308
- 모병
- Emory University Hospital Midtown
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University Hospital
-
Atlanta, Georgia, 미국, 30322
- 모병
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- The James Cancer Hospital and Solove Research Institute
-
Columbus, Ohio, 미국, 43210
- 모병
- Ohio State University Hospitals
-
Columbus, Ohio, 미국, 43210
- 모병
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, 미국, 37203
- 모병
- Tristar BMT
-
Nashville, Tennessee, 미국, 37203
- 모병
- SCRI Oncology Partners
-
Nashville, Tennessee, 미국, 37203
- 모병
- TriStar Centennial Medical center
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- 모병
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8V 5C2
- 아직 모집하지 않음
- Juravinski Cancer Centre
-
Toronto, Ontario, 캐나다, M5G2M9
- 모병
- University Health Network- Princess Margaret Cancer Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
실험적: Part 2
Monotherapy Dose Escalation |
Oral administration |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
기간: Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
International Myeloma Working Group (IMWG) 반응 기준에 따른 조사자 판단 객관적 반응률 (ORR)
기간: 기준선부터 질병 진행의 첫 번째 문서화, 사망 또는 새로운 항암 치료 시작까지의 기간 (약 2년)
|
기준선부터 질병 진행의 첫 번째 문서화, 사망 또는 새로운 항암 치료 시작까지의 기간 (약 2년)
|
|
|
조사관이 결정한 국제 골수종 작업 그룹(IMWG) 반응 기준에 따른 완전 반응률(CRR)
기간: 기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작이 최초로 문서화된 날짜까지 (약 2년)
|
기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작이 최초로 문서화된 날짜까지 (약 2년)
|
|
|
연구자가 결정한 IMWG 기준 반응 시간(TTR)
기간: 기준선부터 질병 진행의 첫 번째 문서화 날짜, 사망 또는 새로운 항암 치료 시작까지(약 2년)
|
기준선부터 질병 진행의 첫 번째 문서화 날짜, 사망 또는 새로운 항암 치료 시작까지(약 2년)
|
|
|
조사관이 결정한 IMWG 기준에 따른 반응 지속 기간(DOR)
기간: 기초선부터 질병 진행의 첫 번째 문서화 날짜, 사망 또는 새로운 항암 치료 시작까지(약 2년)
|
기초선부터 질병 진행의 첫 번째 문서화 날짜, 사망 또는 새로운 항암 치료 시작까지(약 2년)
|
|
|
조사자가 결정한 IMWG 기준 완전 반응 지속 기간 (DOCR)
기간: 기준선부터 질병 진행, 사망 또는 새로운 항암 요법 시작의 첫 번째 문서화 날짜까지 (약 2년)
|
기준선부터 질병 진행, 사망 또는 새로운 항암 요법 시작의 첫 번째 문서화 날짜까지 (약 2년)
|
|
|
연구자에 의해 결정된 IMWG 기준 무진행 생존(PFS)
기간: 기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작이 처음 문서화된 날까지 (약 2년)
|
기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작이 처음 문서화된 날까지 (약 2년)
|
|
|
전체 생존율(OS)
기간: 기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작을 처음으로 문서화한 날짜까지 (약 2년)
|
기준선부터 질병 진행, 사망 또는 새로운 항암 치료 시작을 처음으로 문서화한 날짜까지 (약 2년)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
기간: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- C6331001
- KAT2i (기타 식별자: Alias Study Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .